- Sen. Mitch McConnell Leaves Rehab, Heads Home After Concussion
- AHA News: A Decade After Her Baby’s Heart Surgery, a Surgeon Fixed the Same Problem in Her Heart
- COVID in Pregnancy Might Raise Odds for Neurodevelopmental Disorders in Sons: Study
- Black Americans Would Reap Biggest Health Boon From Cleaner Air
- Sleep Apnea in Childhood Could Affect Developing Brain
- Tick Bites Can Trigger Meat Allergy: What You Need to Know
- Insomnia, Sleep Apnea Rise in Women With MS
- Health Highlights: March 27, 2023
- Ovary Removal When Young Could Raise Parkinson’s Risk
- Loud Incubators Might Damage Preemie Babies’ Hearing
Brain-Imaging Drug Approved for Alzheimer’s Detection

FRIDAY, Oct. 25Vizamyl (flutemetamol F 18 injection) has been approved by the U.S. Food and Drug Administration for use with positron emission tomography (PET) imaging of the brain to screen adults for signs of Alzheimer’s disease and other forms of dementia.
Dementia — characterized by deteriorating memory, judgment, language and motor skills — has been associated with brain accumulation of a protein called beta amyloid. Vizamyl, combined with a PET scan, can help doctors detect this protein, the FDA said Friday in a news release.
Vizamel, the second diagnostic drug approved for this purpose, was evaluated in clinical studies of 761 people. The injected drug is not meant to predict whether a person will go on to develop Alzheimer’s or other types of dementia, or to evaluate how people may respond to dementia therapies, the FDA warned.
Potential side effects of the drug include allergic-like reaction, becoming flushed, headache, a rise in blood pressure, nausea and dizziness, the agency said.
Vizamyl is produced for GE Healthcare by Medi-Physics Inc., based in Arlington Heights, Ill.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2023 HealthDay. All rights reserved.